{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:09:04Z","timestamp":1758874144219},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s12012-024-09876-z","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T17:01:49Z","timestamp":1718470909000},"page":"757-765","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiotoxicity of HER2-Targeted Drugs When Combined with Other Drugs: A Systematic and Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"24","author":[{"given":"Jiakun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengyuan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xv","family":"Yidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"issue":"4785","key":"9876_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science, 235(4785), 177\u2013182. https:\/\/doi.org\/10.1126\/science.3798106","journal-title":"Science"},{"issue":"2","key":"9876_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3747\/co.23.2743","volume":"23","author":"R Haq","year":"2016","unstructured":"Haq, R., & Gulasingam, P. (2016). Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission. Current Oncology (Toronto, Ont)., 23(2), 91\u20135. https:\/\/doi.org\/10.3747\/co.23.2743","journal-title":"Current Oncology (Toronto, Ont)."},{"issue":"1","key":"9876_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188549","volume":"1876","author":"Y Zhu","year":"2021","unstructured":"Zhu, Y., Zhu, X., Wei, X., Tang, C., & Zhang, W. (2021). HER2-targeted therapies in gastric cancer. Biochimica et Biophysica Acta - Reviews on Cancer, 1876(1), 188549. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188549","journal-title":"Biochimica et Biophysica Acta - Reviews on Cancer"},{"issue":"34","key":"9876_CR4","doi-asserted-by":"publisher","first-page":"5700","DOI":"10.1200\/jco.2009.23.2025","volume":"27","author":"AM Gonzalez-Angulo","year":"2009","unstructured":"Gonzalez-Angulo, A. M., Litton, J. K., Broglio, K. R., Meric-Bernstam, F., Rakkhit, R., Cardoso, F., Peintinger, F., Hanrahan, E. O., Sahin, A., Guray, M., Larsimont, D., Feoli, F., Stranzl, H., Buchholz, T. A., Valero, V., Theriault, R., Piccart-Gebhart, M., Ravdin, P. M., Berry, D. A., & Hortobagyi, G. N. (2009). High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. Journal of Clinical Oncology, 27(34), 5700\u20135706. https:\/\/doi.org\/10.1200\/jco.2009.23.2025","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"9876_CR5","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","volume":"23","author":"AU Buzdar","year":"2005","unstructured":"Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., Cristofanilli, M., Frye, D. K., Smith, T. L., Hunt, K. K., Singletary, S. E., Sahin, A. A., Ewer, M. S., Buchholz, T. A., Berry, D., & Hortobagyi, G. N. (2005). Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. Journal of Clinical Oncology, 23(16), 3676\u20133685. https:\/\/doi.org\/10.1200\/JCO.2005.07.032","journal-title":"Journal of Clinical Oncology"},{"issue":"4785","key":"9876_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science, 235(4785), 177\u2013182. https:\/\/doi.org\/10.1126\/science.3798106","journal-title":"Science"},{"key":"9876_CR7","volume-title":"Goldman-cecil medicine","author":"L Goldman","year":"2015","unstructured":"Goldman, L., & Schafer, A. I. (2015). Goldman-cecil medicine. Maryland Heights: Elsevier Gezondheidszorg."},{"issue":"23","key":"9876_CR8","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.3969\/j.issn.1000-8179.2012.23.021","volume":"39","author":"Q Fu","year":"2012","unstructured":"Fu, Q., Xia, S., Li, C., & Yu, S. (2012). Analysis of long-term cardiotoxicity of adjuvant trastuzumab therapy in HER2-positive breast cancer patients. Chinese Journal of Clinical Oncology, 39(23), 1952\u20135. https:\/\/doi.org\/10.3969\/j.issn.1000-8179.2012.23.021","journal-title":"Chinese Journal of Clinical Oncology"},{"issue":"19","key":"9876_CR9","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1002\/cncr.33102","volume":"126","author":"S Kunte","year":"2020","unstructured":"Kunte, S., Abraham, J., & Montero, A. J. (2020). Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Cancer, 126(19), 4278\u20134288. https:\/\/doi.org\/10.1002\/cncr.33102","journal-title":"Cancer"},{"key":"9876_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.821663","volume":"8","author":"M Lin","year":"2021","unstructured":"Lin, M., Xiong, W., Wang, S., Li, Y., Hou, C., Li, C., & Li, G. (2021). The research progress of trastuzumab-induced cardiotoxicity in HER-2-positive breast cancer treatment. Frontiers in cardiovascular medicine., 8, 821663. https:\/\/doi.org\/10.3389\/fcvm.2021.821663","journal-title":"Frontiers in cardiovascular medicine."},{"issue":"7","key":"9876_CR11","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.26355\/eurrev_201804_14752","volume":"22","author":"MA Nicolazzi","year":"2018","unstructured":"Nicolazzi, M. A., Carnicelli, A., Fuorlo, M., Scaldaferri, A., Masetti, R., Landolfi, R., & Favuzzi, A. M. R. (2018). Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. European Review for Medical and Pharmacological Sciences, 22(7), 2175\u201385. https:\/\/doi.org\/10.26355\/eurrev_201804_14752","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"9876_CR12","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 2017. Retrieved September 1, 2020, from https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"9876_CR13","first-page":"253","volume-title":"Nomenclature and criteria for diagnosis of diseases of the heart and great vessels","author":"The Criteria Committee of the New York Heart Association","year":"1994","unstructured":"The Criteria Committee of the New York Heart Association. (1994). Nomenclature and criteria for diagnosis of diseases of the heart and great vessels (9th ed., pp. 253\u2013256). Little Brown & Co.","edition":"9"},{"issue":"1","key":"9876_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996). Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials, 17(1), 1\u201312. https:\/\/doi.org\/10.1016\/0197-2456(95)00134-4","journal-title":"Controlled Clinical Trials"},{"key":"9876_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ED000142","author":"M Cumpston","year":"2019","unstructured":"Cumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P. T., & Thomas, J. (2019). Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database of Systematic Reviews. https:\/\/doi.org\/10.1002\/14651858.ED000142","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"35","key":"9876_CR16","doi-asserted-by":"publisher","first-page":"S4306","DOI":"10.21037\/jtd.2018.10.06","volume":"10","author":"D Cardinale","year":"2018","unstructured":"Cardinale, D., Caruso, V., & Cipolla, C. M. (2018). The breast cancer patient in the cardioncology unit. Journal of Thoracic Disease, 10(35), S4306\u2013S4322. https:\/\/doi.org\/10.21037\/jtd.2018.10.06","journal-title":"Journal of Thoracic Disease"},{"issue":"19","key":"9876_CR17","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/jnci\/djn310","volume":"100","author":"AC Mertens","year":"2008","unstructured":"Mertens, A. C., Liu, Q., Neglia, J. P., Wasilewski, K., Leisenring, W., Armstrong, G. T., Robison, L. L., & Yasui, Y. (2008). Cause-specific late mortality among 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study. Journal of the National Cancer Institute., 100(19), 1368\u20131379. https:\/\/doi.org\/10.1093\/jnci\/djn310","journal-title":"Journal of the National Cancer Institute."},{"issue":"3","key":"9876_CR18","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/bcr2901","volume":"13","author":"JL Patnaik","year":"2011","unstructured":"Patnaik, J. L., Byers, T., DiGuiseppi, C., Dabelea, D., & Denberg, T. D. (2011). Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study. Breast cancer research\u202f: BCR., 13(3), R64. https:\/\/doi.org\/10.1186\/bcr2901","journal-title":"Breast cancer research : BCR."},{"issue":"1","key":"9876_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","volume":"188","author":"N Dempsey","year":"2021","unstructured":"Dempsey, N., Rosenthal, A., Dabas, N., Kropotova, Y., Lippman, M., & Bishopric, N. H. (2021). Trastuzumab-induced cardiotoxicity: A review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Research and Treatment, 188(1), 21\u201336. https:\/\/doi.org\/10.1007\/s10549-021-06280-x","journal-title":"Breast Cancer Research and Treatment"},{"issue":"32","key":"9876_CR20","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1200\/JCO.20.00184","volume":"38","author":"M Sawaki","year":"2020","unstructured":"Sawaki, M., Taira, N., Uemura, Y., Saito, T., Baba, S., Kobayashi, K., Kawashima, H., Tsuneizumi, M., Sagawa, N., Bando, H., et al. (2020). Randomized controlled trial of trastuzumab with or without chemotherapy for HER2-positive early breast cancer in older patients. Journal of Clinical Oncology., 38(32), 3743\u20133752. https:\/\/doi.org\/10.1200\/JCO.20.00184","journal-title":"Journal of Clinical Oncology."},{"issue":"8\u20139","key":"9876_CR21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1159\/000318144","volume":"33","author":"M Clemens","year":"2010","unstructured":"Clemens, M., Eidtmann, H., Nitz, U., Niederle, N., du Bois, A., Grischke, E. M., Hinke, A., & von Minckwitz, G. (2010). Trastuzumab single-drug therapy after failure of cytotoxic treatment for metastatic breast cancer. Onkologie, 33(8\u20139), 425\u2013430. https:\/\/doi.org\/10.1159\/000318144","journal-title":"Onkologie"},{"key":"9876_CR22","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2018.06.06","author":"T Reinert","year":"2018","unstructured":"Reinert, T., de Paula, B., Shafaee, M. N., Souza, P. H., Ellis, M. J., & Bines, J. (2018). Endocrine therapy for ER-positive\/HER2-negative metastatic breast cancer. Chinese Clinical Oncology. https:\/\/doi.org\/10.21037\/cco.2018.06.06","journal-title":"Chinese Clinical Oncology"},{"issue":"33","key":"9876_CR23","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.1200\/jco.2008.20.6847","volume":"27","author":"B Kaufman","year":"2009","unstructured":"Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., R\u00e9vil, C., & Jones, A. (2009). Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. Journal of Clinical Oncology, 27(33), 5529\u20135537. https:\/\/doi.org\/10.1200\/jco.2008.20.6847","journal-title":"Journal of Clinical Oncology"},{"key":"9876_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204764","author":"U Hafeez","year":"2020","unstructured":"Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020). Antibody-drug conjugates for cancer therapy. Molecules. https:\/\/doi.org\/10.3390\/molecules25204764","journal-title":"Molecules"},{"issue":"6","key":"9876_CR25","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/s1470-2045(16)30030-4","volume":"17","author":"A Thomas","year":"2016","unstructured":"Thomas, A., Teicher, B. A., & Hassan, R. (2016). Antibody-drug conjugates for cancer therapy. The lancet Oncology, 17(6), e254\u2013e262. https:\/\/doi.org\/10.1016\/s1470-2045(16)30030-4","journal-title":"The lancet Oncology"},{"issue":"4","key":"9876_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ccl.2019.07.005","volume":"37","author":"R Barish","year":"2019","unstructured":"Barish, R., Gates, E., & Barac, A. (2019). Trastuzumab-induced cardiomyopathy. Cardiology Clinics, 37(4), 407\u2013418. https:\/\/doi.org\/10.1016\/j.ccl.2019.07.005","journal-title":"Cardiology Clinics"},{"issue":"9","key":"9876_CR27","doi-asserted-by":"publisher","first-page":"H1453","DOI":"10.1152\/ajpheart.00554.2015","volume":"309","author":"ZV Varga","year":"2015","unstructured":"Varga, Z. V., Ferdinandy, P., Liaudet, L., & Pacher, P. (2015). Drug-induced mitochondrial dysfunction and cardiotoxicity. American Journal of Physiology. Heart and Circulatory Physiology, 309(9), H1453\u2013H1467. https:\/\/doi.org\/10.1152\/ajpheart.00554.2015","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"issue":"1","key":"9876_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10741-019-09906-x","volume":"26","author":"K Fang","year":"2021","unstructured":"Fang, K., Zhang, Y., Liu, W., & He, C. (2021). Effects of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: A meta-analysis of randomized controlled trials. Heart failure reviews., 26(1), 101\u2013109. https:\/\/doi.org\/10.1007\/s10741-019-09906-x","journal-title":"Heart failure reviews."},{"issue":"27","key":"9876_CR29","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1093\/eurheartj\/ehab843","volume":"43","author":"C Lewinter","year":"2022","unstructured":"Lewinter, C., Nielsen, T. H., Edfors, L. R., Linde, C., Bland, J. M., LeWinter, M., Cleland, J. G. F., K\u00f8ber, L., Braunschweig, F., & Mansson-Broberg, A. (2022). A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. European heart journal., 43(27), 2562\u20132569. https:\/\/doi.org\/10.1093\/eurheartj\/ehab843","journal-title":"European heart journal."}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-024-09876-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-024-09876-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-024-09876-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T02:13:59Z","timestamp":1722910439000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-024-09876-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["9876"],"URL":"https:\/\/doi.org\/10.1007\/s12012-024-09876-z","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"type":"print","value":"1530-7905"},{"type":"electronic","value":"1559-0259"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"assertion":[{"value":"7 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests between each others.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The protocol of our systematic review and meta-analysis has been registered in the International prospective register of systematic reviews (PROSPERO), Registration id: CRD42022323096. Neither consent to participant nor publish is applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}